Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
Press Releases
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Press Releases
Filter by Year:
2024
2023
2-Dec-2023
Kazia Therapeutics Announces $2 Million Registered Direct Offering
1-Dec-2023
Kazia AGM - Chairman's Address
1-Dec-2023
Kazia 2023 Annual General Meeting R&D and Clinical Overview
1-Dec-2023
Kazia AGM Meeting results
29-Nov-2023
Kazia Announces Non-binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology
21-Nov-2023
Kazia Provides Overview Of Paxalisib Related Presentations from the Society Of Neuro-oncology 2023 Annual Meeting
1
